Header Logo

Connection

Leslie Shaw to Graft Rejection

This is a "connection" page, showing publications Leslie Shaw has written about Graft Rejection.
Connection Strength

1.236
  1. Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation. 2010 Jul 15; 90(1):31-7.
    View in: PubMed
    Score: 0.308
  2. DeNofrio D, Loh E, Kao A, Korecka M, Pickering FW, Craig KA, Shaw LM. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000 Nov; 19(11):1071-6.
    View in: PubMed
    Score: 0.157
  3. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000 Feb; 22(1):14-9.
    View in: PubMed
    Score: 0.149
  4. Shaw LM, Korecka M, Aradhye S, Grossman R, Barker C, Naji A, Brayman KL. Scientific principles for mycophenolic acid therapeutic drug monitoring. Transplant Proc. 1998 Aug; 30(5):2234-6.
    View in: PubMed
    Score: 0.134
  5. Shaw LM, Audet PR, Grossman RA, Fields L, Lensmeyer GL, Dafoe DC. Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility. Transplant Proc. 1990 Jun; 22(3):1267-73.
    View in: PubMed
    Score: 0.076
  6. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001 Aug; 23(4):305-15.
    View in: PubMed
    Score: 0.041
  7. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001 May; 41(5):542-51.
    View in: PubMed
    Score: 0.041
  8. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001 Feb; 34(1):17-22.
    View in: PubMed
    Score: 0.040
  9. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem. 1998 Jul; 31(5):317-22.
    View in: PubMed
    Score: 0.033
  10. Shaw LM, Korecka M, van Breeman R, Nowak I, Brayman KL. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem. 1998 Jul; 31(5):323-8.
    View in: PubMed
    Score: 0.033
  11. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998 Feb; 44(2):381-7.
    View in: PubMed
    Score: 0.032
  12. Weber M, Deng S, Arenas J, Aradhye S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. Transplant Proc. 1997 Dec; 29(8):3669-70.
    View in: PubMed
    Score: 0.032
  13. Weber M, Ketchum RJ, Sellers M, Aradhye S, Deng S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients. Transplant Proc. 1997 Feb-Mar; 29(1-2):338-9.
    View in: PubMed
    Score: 0.030
  14. Shaw LM. Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. Drug Metabol Drug Interact. 1997; 14(1):33-40.
    View in: PubMed
    Score: 0.030
  15. Heifets M, Cooney GF, Shaw LM, Libetti G. Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. Transplantation. 1995 Dec 27; 60(12):1615-7.
    View in: PubMed
    Score: 0.028
  16. Shaw LM, Brayman KL. FK-506 therapeutic drug monitoring. Clin Chem. 1994 Dec; 40(12):2207-8.
    View in: PubMed
    Score: 0.026
  17. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
    View in: PubMed
    Score: 0.018
  18. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006 Apr; 28(2):145-54.
    View in: PubMed
    Score: 0.014
  19. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002 Feb; 24(1):59-67.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.